Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,308,124

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,308,124
Title:Apparatus and methods for delivering therapeutic agents
Abstract: In various embodiments, a drug-delivery device includes one or more reservoirs that may each contain a therapeutic agent for delivery to a patient.
Inventor(s): Humayun; Mark (Glendale, CA), Caffey; Sean (Manhattan Beach, CA)
Assignee: University of Southern California (Los Angeles, CA)
Application Number:12/340,095
Patent Claims:1. A method for treating an ophthalmic condition, comprising: implanting a drug-delivery device in a patient's eye, the device comprising (i) a refillable reservoir having a self-resealing upper layer that is pierceable by a needle for refilling and an opposed lower layer that is unpuncturable by the needle so as to protect the eye from injury, (ii) a tapered cannula in fluid communication with the reservoir, and (iii) a valve disposed in the cannula, wherein the valve controls fluid delivery, maintains a constant flow rate independent of variations in pressure driving a fluid flow through the cannula, and prevents backflow; and filling the reservoir with a liquid that comprises a therapeutic agent selected from the group consisting of acetazolamide, betaxolol, bevacizumab, bimatoprost, brimonidine, brinzolamide, carbidopa, carteolol, cidofovir, cyclosporine, dorzolamide, epinephrine, ketorolac tromethamine, ketotifen fumarate, latanoprost, levobetaxolol, levobunolol, levodopa, levofloxacin, loratadine, loteprednol etabonate, metipranolol, naphazoline, ofloxacin, pegaptanib, pemirolast, pheniramine maleate, pilocarpine, pseudoephedrine, ranibizumab, a steroid, timolol, travoprost, trifluridine, unoprostone isopropyl, valganciclovir, verteporfin, vitravene, a drug that prevents beta amyloid deposition in the retina, an anti-human complement activation blocker that blocks complement H activation in the eye, and siRNA molecules, wherein the device is implanted with the lower layer placed adjacent to the sclera of the eye and the cannula inserted into the eye through the sclera to facilitate delivery of drug from the reservoir into the eye.

2. The method of claim 1, further comprising directing the liquid to a target site via the cannula.

3. The method of claim 1, further comprising: (i) executing a stored drug-delivery regimen including a delivery pressure and a delivery flow rate of the liquid, (ii) receiving feedback from the patient, and (iii) modifying the stored drug-delivery regimen based on the feedback.

4. The method of claim 1, further comprising: (i) detecting the patient's position and activity; (ii) determining at least one of a frequency, time, or dosage of the liquid delivered to the patient based thereon; and (iii) responsively controlling delivery of the liquid.

5. The method of claim 4, wherein a dosage of the delivered liquid is controlled, at a constant flow rate, based on a duration that the liquid flows through the cannula.

Details for Patent 9,308,124

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Sign up for a Free Trial 2027-12-20
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2006-06-30 ⤷  Sign up for a Free Trial 2027-12-20
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2012-08-10 ⤷  Sign up for a Free Trial 2027-12-20
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2016-10-13 ⤷  Sign up for a Free Trial 2027-12-20
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2018-03-20 ⤷  Sign up for a Free Trial 2027-12-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.